Changes in Hong Kong stocks | True Healthcare-B (02697) rose more than 8% in the intraday period to reach a new high room temperature multi-organ infusion platform, and a major order landed

The Zhitong Finance App learned that True Healthcare-B (02697) rose more than 8% in the intraday period, reaching a record high of HK$886, and its total market capitalization surpassed HK$30 billion. It is worth noting that the stock has continued to be sought after by market capital recently, and the cumulative increase since the beginning of August has exceeded 50%.

According to the news, recently, the organ room temperature perfusion system independently developed by True Health Medical officially won the bid for Yunnan Agricultural University's “Yunnan Key Laboratory of Small Pig Gene Editing and Heterologous Organ Transplantation Research Equipment Procurement Project No. 2026-73”, with a transaction amount of 2.8 million yuan, indicating that True Health Medical's room temperature multi-organ injection platform has fully passed engineering verification and cutting-edge application scenario verification.

Zhitong Finance App in “Heavy Order Landed! “True Health Medicine (02697) Leads the New Track for Organ Room Temperature Infusion and Draws the Second Growth Curve” indicates that with the implementation of this system and the advancement of industrialization, the room temperature mechanical injection business is accelerating to become another strong growth pole for real health care after surgical robots, opening up an infinite space for commercial imagination. With the absolute first-mover advantage of “technology pioneering”, True Health Medical is transforming from a medical robot company to a leading full-range high-end diagnosis and treatment equipment company covering “diagnosis and treatment robots+cutting-edge organ life support systems”.